Is rechallenge with anti–epidermal growth factor receptor (EGFR) inhibitors a therapeutic option in patients with refractory circulating tumor DNA (ctDNA) RAS/BRAF wild-type (wt) colorectal cancer (CRC)? Here, EGFR is linked to neoplasm.